Can Circulating Tumor DNA Inform Breast Cancer Treatment?

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.

In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Related Content
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Radhika Appaya;Sarah Sammons, MD;Priyanka Sharma, MD;Yara Abdou;VK Gadi, MD, PhD;Taavy A. Miller;Spencer S. Langerman;Dominick Latremouille-Viau;Annie Guerin;Carmine Rossi;Emily McGovern;Gary Sopher;Vamsi Bollu;Natalia Bolotova;Şerban R. Iorga;Liz Santarsiero;Susan Dent, MD
June 30th 2025
Article

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes

ONCOLOGY Staff
June 29th 2025
Article

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.